|
Collaborators and colleagues with related research interests |
|
Peter M. Blumberg, Ph.D. Dr. Blumberg is the Head of the Molecular Mechanisms of Tumor Promotion Section in the Laboratory of Cellular Carcinogenesis and Tumor Promotion at the National Cancer Institute, NIH, in Bethesda, MD. Dr. Blumberg’s research interest in in the mechanism of action of phorbol esters and related derivatives. For more information visit the Blumberg Website. |
|
Victor E. Marquez, Ph.D. Dr. Marquez is the Head of the Organic Chemistry Section in the Laboratory of Medicinal Chemistry at the National Cancer Institute, NIH, in Frederick, MD. Dr. Marquez’s research interest is in the rational design of antitumor and antiviral agents. For more information, visit the Marquez Website. |
|
James C. Stone, Ph.D. Dr. Stone is Professor in the Department of Biochemistry at the School of Medicine and Dentistry, University of Alberta, Canada. His research interest in in neoplastic transformation by dominant oncogenes. His lab discovered RasGRP1 in 1998. For more information about the Stone Lab , click here. |
|
Marcelo G. Kazanietz, Ph.D. Dr. Kazanietz is Associate Professor in the Department of Pharmacology at the University of Pennsylvania School of Medicine, in Philadelphia, PA. His lab is interested in the role of PKC and chimaerins in cancer. For more information visit The Kazanietz Laboratory website. |
|
Chaya Brodie, Ph.D. Dr. Brodie is the Laboratory Director of the William & Karen Davidson Laboratory of Brain Tumor Biology, in the Hermelin Brain Tumor Center at Henry Ford Neuroscience Institute, Detroit, MO. Dr. Brodie’s work focuses on three major areas: PKC signaling in astrocytic tumors; RTVP-1 a novel diagnostic marker and a therapeutic target for the treatment of gliomas, and novel approaches for the imaging, targeting and therapy of glioma cells using peptide-conjugated magnetic nanoparticles. For more information, click here. |